SGC GAK 1 is a high affinity cyclin G associated kinase (GAK) inhibitor that targets the ATP-binding site.

BAY-1816032 (BAY1816032) is a novel, potent and oral bioavailable inhibitor of BUB1 (budding uninhibited by benzimidazoles 1) kinase with anticancer effects.

Hepln-13 (Hepln13; Hepln 13) is a novel, orally bioactive and potent hepsin inhibitor (IC50 = 0.33 µM) with potential anticancer activity.

STK16-IN-1 is a novel and highly selective ATP competitive inhibitor of STK16 kinase with an IC50 of 295 nM.

ML-281, a quinoxalinone derivative, is a novel, potent and selective STK33 inhibitor with IC50 value of 14 nM.

HPK1-IN-2 is a novel,potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity.